Log in

NASDAQ:CNMDCONMED Stock Price, Forecast & News

$73.01
+0.54 (+0.75 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$72.41
Now: $73.01
$74.56
50-Day Range
$66.62
MA: $72.93
$81.76
52-Week Range
$37.66
Now: $73.01
$116.81
Volume225,700 shs
Average Volume434,045 shs
Market Capitalization$2.08 billion
P/E Ratio76.85
Dividend Yield1.10%
Beta0.56
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and VCARE uterine manipulator for enhancing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers endoscopic technologies offering, including diagnostic and therapeutic products for use in gastroenterology procedures; cardiology and critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company markets its products directly to surgeons, hospitals, surgery centers, group purchasing organizations, integrated delivery networks, and other customers, as well as through medical specialty distributors. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.
Read More
CONMED logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.85 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:CNMD
CUSIP20741010
Phone315-797-8375

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$955.10 million
Cash Flow$3.19 per share
Book Value$23.54 per share

Profitability

Net Income$28.62 million

Miscellaneous

Employees3,100
Market Cap$2.08 billion
Next Earnings Date7/29/2020 (Confirmed)
OptionableOptionable

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

CONMED (NASDAQ:CNMD) Frequently Asked Questions

How has CONMED's stock been impacted by COVID-19 (Coronavirus)?

CONMED's stock was trading at $78.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CNMD stock has decreased by 7.3% and is now trading at $73.01. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CONMED?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CONMED.

When is CONMED's next earnings date?

CONMED is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for CONMED.

How can I listen to CONMED's earnings call?

CONMED will be holding an earnings conference call on Wednesday, July 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) issued its earnings results on Wednesday, April, 29th. The medical technology company reported $0.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.44 by $0.07. The medical technology company earned $214 million during the quarter, compared to analyst estimates of $214.85 million. CONMED had a return on equity of 11.18% and a net margin of 3.00%. The business's quarterly revenue was down 2.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.57 earnings per share. View CONMED's earnings history.

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED announced a quarterly dividend on Friday, May 22nd. Stockholders of record on Monday, June 15th will be paid a dividend of $0.20 per share on Monday, July 6th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.10%. The ex-dividend date is Friday, June 12th. View CONMED's dividend history.

What price target have analysts set for CNMD?

7 Wall Street analysts have issued 1-year price objectives for CONMED's shares. Their forecasts range from $76.00 to $115.00. On average, they expect CONMED's stock price to reach $97.17 in the next twelve months. This suggests a possible upside of 33.1% from the stock's current price. View analysts' price targets for CONMED.

Has CONMED been receiving favorable news coverage?

News headlines about CNMD stock have been trending negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CONMED earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the medical technology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about CONMED.

Who are some of CONMED's key competitors?

What other stocks do shareholders of CONMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CONMED investors own include AbbVie (ABBV), Bausch Health Companies (BHC), Gilead Sciences (GILD), Incyte (INCY), Moody's (MCO), Neurocrine Biosciences (NBIX), AT&T (T), Verizon Communications (VZ), Zoetis (ZTS) and Align Technology (ALGN).

Who are CONMED's key executives?

CONMED's management team includes the following people:
  • Mr. Curt R. Hartman, CEO, Pres & Director (Age 55)
  • Mr. Todd W. Garner, Exec. VP & CFO (Age 50)
  • Mr. Patrick J. Beyer, Pres of CONMED International (Age 53)
  • Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 44)
  • Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 44)

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

Who are CONMED's major shareholders?

CONMED's stock is owned by many different institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.09%). Company insiders that own CONMED stock include Daniel Jonas, Dirk Kuyper, Heather L Cohen, John Jed Kennedy, John L Workman, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III, Terence M Berge and Wilfredo Ruiz-Caban. View institutional ownership trends for CONMED.

Which institutional investors are buying CONMED stock?

CNMD stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought CONMED stock in the last two years include Heather L Cohen, and John L Workman. View insider buying and selling activity for CONMED.

How do I buy shares of CONMED?

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $73.01.

How big of a company is CONMED?

CONMED has a market capitalization of $2.08 billion and generates $955.10 million in revenue each year. The medical technology company earns $28.62 million in net income (profit) each year or $2.64 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

What is CONMED's official website?

The official website for CONMED is www.conmed.com.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.